TPPU: Benchmark Soluble Epoxide Hydrolase Inhibitor for Inflammatory Pain & Redox Research

Executive Summary: TPPU (N-[1-(1-oxopropyl)-4-piperidinyl]-N’-[4-(trifluoromethoxy)phenyl]-urea) is a highly selective and potent sEH inhibitor (IC50: 3.7 nM human, 2.8 nM mouse) enabling precise modulation of fatty acid epoxide metabolism in preclinical research (APExBIO). Inhibition of sEH by TPPU increases endogenous epoxyeicosatrienoic acids (EETs), counteracting inflammation and osteoclastogenesis (Liu et al., 2025). TPPU has demonstrated superior pharmacokinetics and efficacy compared to earlier sEH inhibitors, supporting its adoption in pain, cardiovascular, and bone disease models (Redefining sEH Inhibition). The compound is available as a crystalline solid, highly soluble in DMSO and ethanol, and must be stored at -20°C. No clinical trials have been reported; TPPU is intended solely for research purposes.

Biological Rationale

Soluble epoxide hydrolase (sEH) is an enzyme that hydrolyzes bioactive lipid epoxides, notably epoxyeicosatrienoic acids (EETs), into less active diols (e.g., 14,15-DHET). EETs are endogenous lipid mediators involved in anti-inflammatory, vasodilatory, and cytoprotective signaling (Liu et al., 2025). Elevated sEH activity reduces EET levels, promoting inflammation and oxidative stress. Inhibition of sEH restores EET concentrations, thereby shifting the balance toward anti-inflammatory and antioxidant effects. Recent research links hepatic sEH activity to osteoclastogenesis via suppression of the Nrf2-ARE pathway, implicating sEH as a cross-organ modulator of bone homeostasis and chronic inflammation (Liu et al., 2025).

Mechanism of Action of TPPU

TPPU is a competitive inhibitor of sEH, binding to the enzyme’s hydrolase domain and preventing the conversion of EETs (e.g., 14,15-EET) to their corresponding diols (e.g., 14,15-DHET). By preserving EET levels, TPPU indirectly reduces pro-inflammatory cytokine expression (TNF-α, IL-6, IL-1β) and enhances Nrf2-mediated antioxidant signaling (Liu et al., 2025). The broad physiological consequences include attenuation of inflammatory pain, suppression of oxidative stress, and modulation of osteoclast differentiation in preclinical models. TPPU’s nanomolar efficacy in both human and mouse sEH assays (IC50: 3.7 nM, 2.8 nM) highlights its translational relevance (APExBIO).

Evidence & Benchmarks

• TPPU inhibits human sEH with an IC50 of 3.7 nM and mouse sEH with an IC50 of 2.8 nM (APExBIO, product page).
• In an OVX-induced osteoporosis mouse model, sEH inhibition by TPPU restored plasma 14,15-EET levels, reduced 14,15-DHET, and decreased pro-inflammatory cytokines (Liu et al., 2025, DOI).
• sEH inhibitors such as TPPU activate the Nrf2-ARE signaling pathway, suppressing osteoclast differentiation (Liu et al., 2025, DOI).
• TPPU and analogs outperform morphine in animal inflammatory pain models in terms of efficacy and pharmacokinetics (TPPU: A Potent sEH Inhibitor).
• TPPU is highly soluble in DMSO (≥120 mg/mL) and ethanol (≥54.8 mg/mL), but insoluble in water (APExBIO, product page).

While previous reviews (TPPU: A Potent sEH Inhibitor for Inflammation) discuss sEH inhibition broadly, this article provides updated mechanistic detail and direct benchmarks for TPPU, especially regarding the hepatic sEH-Nrf2-bone axis and translational model selection.

Applications, Limits & Misconceptions

Applications

• Inflammatory pain research: TPPU is validated in rodent models of inflammatory and neuropathic pain, showing robust analgesic effects (see details).
• Chronic inflammation and metabolic disease models: By modulating EET/DHET ratios, TPPU enables the study of lipid signaling in metabolic syndrome and cardiovascular dysfunction (Redefining sEH Inhibition).
• Bone homeostasis/osteoclastogenesis research: TPPU is instrumental for dissecting the hepatic sEH-Nrf2-bone axis, as shown in liver-specific sEH knockdown models (Liu et al., 2025).
• Cardiovascular and neuroinflammation studies: TPPU’s ability to modulate endogenous EETs supports its use in stroke, atherosclerosis, and neuroinflammatory preclinical models.

Common Pitfalls or Misconceptions

• TPPU is not a clinical drug: No clinical trials or approved therapeutic uses have been reported as of 2024 (APExBIO).
• Not water-soluble: TPPU is insoluble in water; DMSO or ethanol are required for solution preparation.
• Does not inhibit related epoxide hydrolases: TPPU is highly selective for sEH; it does not target microsomal epoxide hydrolase (mEH).
• Species differences must be considered: Efficacy and pharmacokinetics may vary between rodent and human models; dosing optimization is necessary.
• For research use only: TPPU is not suitable for diagnostic, therapeutic, or veterinary applications.

Workflow Integration & Parameters

TPPU is supplied as a crystalline solid (APExBIO, C5414), with a molecular weight of 359.3 Da and formula C16H20F3N3O3. For experimental use, dissolve TPPU in DMSO (≥120 mg/mL) or ethanol (≥54.8 mg/mL). Prepare working solutions fresh, and store stock at -20°C in a desiccated environment. For in vivo studies, TPPU can be formulated in PEG400 or other compatible vehicles after primary dissolution. Dosage and administration must be optimized for each model; published protocols generally range from 0.1–10 mg/kg in rodent studies, depending on the route and study design (Redefining sEH Inhibition). Analytical monitoring of EET/DHET ratios is recommended to confirm target engagement.

Conclusion & Outlook

TPPU establishes a modern benchmark for potent and selective sEH inhibition in translational research. Its validated utility spans inflammatory pain, metabolic, bone, and cardiovascular disease models, driven by nanomolar potency and robust chemical stability. APExBIO provides comprehensive technical support for TPPU (C5414), ensuring reproducibility and high experimental fidelity. While not yet in clinical use, TPPU remains a strategic tool for dissecting lipid mediator signaling and developing novel therapeutic approaches. For further technical detail and updated references, consult the TPPU product page or recent reviews extending the discussion to emerging axes like the liver-bone connection (Redefining sEH Inhibition).